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Abstract
Since the publication of our previous paper, Visual cycle proteins: Structure, function, and roles in human retinal
disease (Tsin, et.al, JBC 293:13016, 2018) there has been significant progress on multiple topics discussed in
this paper. In the present communication, we further explore research advances on two visual cycle proteins:
DES1 and IRBP. In addition, we emphasize the progress of clinical translation of other visual cycle protein
research, including the breakthrough of FDA-approved gene therapy for Leber’s congenital amaurosis, and
additional gene therapies at different stages of clinical trials for various retinal diseases such as retinitis
pigmentosa, diabetic retinopathy, and Stargardt’s disease.
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Since the publication of Visual cycle proteins: Structure, function, and roles in human retinal disease,
there have been significant advances in research involving visual cycle proteins and the translation of
basic science discoveries into treatment of retinal diseases, especially in terms of gene therapy. In our
prior review article, specific visual cycle proteins, their gene mutations, and novel gene therapy treatments
were summarized. Additional investigations, many of which involve clinical trials, have provided further
information on the translational potential of visual cycle protein research to treat retinal diseases.

Recent Advances in Visual Cycle Proteins Research
Interphotoreceptor Retinoid Binding Protein (IRBP)
As the most abundant soluble protein in the interphotoreceptor matrix (IPM), IRBP has been linked
as a major contributor in maintaining the IPM’s integrity [1]. However, the effects of its presence and
absence to visual structures requires further examination. Recently, researchers demonstrated the absence
of IRBP through CRISPR knockout irbp-/- mice and the presence of IRBP in wildtype mice. In irbp/- mice, the structure of the outer segments were abnormally altered, with thinning and change in space
between the structures observed [2]. Because of the role of IRBP as a significant anti-oxidant in the
retina, these results are consistent with others on IRBP-induced oxidative stress affecting the thickness
of subretinal space [3,4].
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A recent publication highlighted the significance of IRBP levels to combat detrimental effects of
diabetes to vision. When examining vitreous and retina samples from healthy non-diabetic and diabetic
patients, researchers discovered that there was a five-fold decrease in the expression of IRBP in patients
with severe diabetic retinopathy (DR) in comparison to patients that did not have diabetes [5]. These
researchers also established that there was a negative correlation between IRBP expression and severity
of DR. Furthermore, a negative correlation between IRBP levels and levels of inflammatory cytokines
(VEGF and IL-6) was also established. Thus, decreased IRBP levels may indicate a lack of resistance to
the development of DR [5]. These novel findings reveal the opportunity to use IRBP as a biomarker when
evaluating and treating DR.

This article is originally published by ProBiologist LLC., and is freely available at probiologists.com
Arch Clin Exp Ophthalmol 2020; 2(3):73-76.
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IRBP is an important visual cycle protein to support visual
function. In a recent study, HMG CoA reductase inhibitor (statin)
simvastatin was found to reduce degeneration of rod photoreceptors
and upregulate levels of IRBP under oxidative stress conditions
induced by all-trans retinal [6]. Specifically, the study discovered
that rod photoreceptors treated with simvastatin first had improved
mitochondrial function when induced with oxidative stress. Further
experiments are needed to investigate the detailed mechanism of
simvastatin’s use in protecting photoreceptor degeneration through
the increase of IRBP expression.
Isomerase enzyme of the intra-retinal visual cycle - DES1
and RGR
Dihydroceramide desaturase 1 (DES1) was considered the
main enzyme involved in the photoisomerization reaction in the
intraretinal/cone visual cycle, as it was thought to convert the retinoid
chromophore back to cis configuration after the chromophore was
converted to trans configuration in the photoisomerization reaction.
It has been shown to convert all-trans-retinol to 11-cis-retinol [7].
However, recent studies using knockout DES1 retinas of mice
and zebrafish show that the cone visual cycle has no interruptions,
suggesting the DES1 does not have a significant role in supplying
visual chromophore for cone pigment regeneration [8,9]. It has
been reported that RGR (Retinal G-protein couple Receptor) opsin,
working with retinol dehydrogenase 10, can provide 11-cis retinal for
cone pigment regeneration in a light activated mechanism in Müller
cells [10].

Clinical Translation of Visual Cycle Protein Mutations Gene Therapy for Retinal Disease
In addition to genetic research performed on mice models,
human gene therapy has allowed for improved prognoses of previously
irreversible blinding diseases such as retinitis pigmentosa, Leber’s
congenital amaurosis, diabetic retinopathy, and Stargardt’s disease.
The progression of gene therapy now exceeds the advancement of
RPE65 gene treatment, with results promising a brighter future in
vision.
Leber’s congenital amaurosis (LCA)
While there are several mutations of visual cycle proteins
associated with Leber’s congenital amaurosis (LCA), LCA caused by
mutations of RPE65 is observed in nearly 6% of cases [11]. Focus on
this pathology mechanism has grown rapidly because of the United
States Food and Drug Administration’s 2017 approval of Luxturna
(voretigene neparvovec-rzyl), a form of one-time gene therapy, to treat
RPE65 mutations in LCA patients. Functional assays can be utilized
to decide which specific RPE65 gene mutations are best suited for
gene therapy in different individuals [12]. In one study, investigators
used functional assays to determine the association between variants
of uncertain significance (VUS) and their impact on RPE65
protein function as an indicator of gene therapy success. Measuring
isomerase activity of RPE65 VUS using functional assays revealed
some patients do not exhibit isomerase activity or proper protein
function. Thus, making certain VUS unsuitable for gene therapy.
In comparison, patients whose RPE65 VUS exhibited isomerase
activity went on to receive successful gene therapy procedures [12].
Usage of functional assays allows for accurate estimation of VUS
pathogenicity to determine gene therapy compatibility.
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One of the markers of LCA is impairment of photoreceptors
due to 11-cis-retinal deficiency and degradation of photoreceptor
cells, often caused by proteasome stress [13]. Knockout mice
models rpe65-/- (LCA2) and lrat -/- (LCA14) with deletion of
M-opsins were used to determine the effects of opsin absence on
photoreceptors. Mice with the deleted M-opsin gene experienced
lower levels of proteasome stress and subsequent preservation of cone
photoreceptors. Since cone opsins are found in higher quantities
than other proteins, they have the largest impact on photoreceptor
viability. However, investigators confirmed that cone photoreceptors
were able to survive without cone opsins [13]. Through closer
examination of this mechanism, there is potential in analyzing other
options in addressing photoreceptor degeneration beyond 11-cisretinal deficiency compensation. Further investigations may be
conducted to pharmaceutically promote proteasome activity and
photoreceptor preservation to supplement gene therapy.
The long term efficacy of gene therapy has been a looming yet
present concern. Investigators recognized that RPE65 gene therapy
was capable of retaining photoreceptors during primary onset
of disease, before any degeneration of photoreceptors. However,
gene therapy in later stages of the disease, when photoreceptor
degeneration transpired, was substantially less effective. A group of
researchers tested gene therapy effects at different stages of RPE65
gene therapy using animal models [14]. After initiating gene therapy
in mutant canines with varying severity of photoreceptor loss and
ages, researchers found that some regions in canine ocular tissue
showed well-preserved photoreceptor nuclei in retinal regions with
high expression of RPE65. Interestingly, the same research group
found retinal regions where photoreceptors were viable with no
RPE65 expression. Researchers noted that it was not the age of
subjects, but the progression of the disease, primarily the extent of
photoreceptor degeneration, that may determine long-term success
of gene therapy [14]. With the current data in canines available,
to translate the study to humans, it is important to consider that
retinal degeneration may still occur even if disease conditions may
be ameliorated.
There have also been new studies that investigate CRISPR
gene-editing application for inherited retinal diseases. A subtype
of LCA, LCA10, has had some recent gene editing advancements
using in-vitro models. LCA10 involves a specific mutation in the
ciliopathy gene CEP290 [15,16]. Most LCA10 patients have the
IVS26 mutation, which creates an erroneous splice in an intron
sequence and results in the non-functional CEP290 protein. A
potential candidate for LCA-type 10 treatment is EDIT-101 [16].
It uses an adeno-associated virus type 5 vector to transmit S. Aureus
Cas9 and CEP290-specific guide RNAs (gRNAs) to photoreceptor
cells via subretinal injection. In this study, researchers recognized
two particular gRNAs that are specific to the CEP290 gene locus,
allowing for the gRNA to efficiently edit the mutated CEP290 in
human cells and retinal tissue. The pairing of SaCas9 and gRNAs to
remove the inaccurate insertion of the intron sequence is shown to
restore the CEP290 gene for proper RNA splicing and consequent
protein expression [16]. Other options in genetic alterations increase
the chances of reversing this inherited retinal disease.
Retinitis pigmentosa (RP)
Previously, we indicated that retinitis pigmentosa (RP)
presents as rod-cone dystrophy, meaning that there is a loss of rod
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photoreceptors before cone photoreceptors. As a result, recent studies
focused on decreasing photoreceptor loss to improve visual function.
The use of gene therapies, using adeno-associated vectors (AAV),
AAV2/5-hPDE6β vector to target roc cGMP phosphodiesterase
6β are currently in phase 1 of clinical trials, with a high possibility
to move on to the final stage of testing (phase 2) [17]. Other gene
therapies currently in phase 1 of clinical trials are the AAV2/5-hRKp
vector and the AAV vector RST-001 (Chop2), of which the latter
is used to increase the photosensitivity gene to treat underlying
conditions found in RP [17,18]. Additionally, current treatments
under investigation include the same voretigene neparvovec-rzyl that
was FDA-approved for LCA treatment, AAV serotype 8 (AAV8)sCX3CL1, and ciliary neurotrophic factor (CNTF)- secreting
neural stem cells (NSC) that have provided potential protection
to photoreceptor cells in RP models [17-19]. The gene therapies
currently under clinical trial demonstrate the promise of possible
cures for RP.
Although RPE65 mutations account for a small percentage
of RP cases, one of the major causes of X-linked RP includes a
mutation on the RP GTPase (RPGR) gene that induces the thinning
of the ONL. Since this gene is not as large as other genes that affect
RP, RPGR has been the target of current research and development
using AAV8 [20,21]. The idea of using AAV8 to transfect a codonoptimized RPGR coding sequence (AAV8-coRPGR) to treat RPGRassociated RP cases is currently being tested on human subjects [21].
Researchers established that patients receiving a higher dosage of the
AAV8-coRPGR treatment showed a greater retention of improved
visual field. Considerable progress has been made in establishing an
alternative gene therapy to correct RP-related visual impairment, but
more testing is needed to verify this prospective treatment.
Diabetic retinopathy (DR)
Previously, we mentioned some of the challenges in treatment
of DR. Diabetic vascular complications remain one of the leading
causes of blindness worldwide, and, although there have been
significant improvements with the advent of anti-VEGF injections,
it is still unclear what factors allow for preventing disease progression.
It has been suggested that anti-VEGF therapies provide protection
to Müller cells thus preventing further neural degradation [22].
Furthermore, researchers discovered that IRBP could block
the damaging effects of VEGF and inflammatory cytokines by
inhibiting tyrosine phosphorylation and by blocking GLUT1 to
halt transportation of sugar into endothelial cells like Müller cells
[5]. With this groundbreaking data, the study demonstrated that
restoring IRBP levels up to physiologic baseline concentrations in
DM rat models could potentially prevent or even reverse retinal
abnormalities like vascular permeability [5]. In another study,
diabetes-induced oxidative stress was attributable to superoxide
from photoreceptors in early phase in the development of diabetic
retinopathy [23]. Nonetheless, gene therapy investigations are
underway to better understand the dynamic pathway leading to
retinal neovascularization and vascular hyperpermeability.
Mesenchymal stem cell therapy has also demonstrated potential
as immunomodulatory agents in DR, illustrating neuroprotective
effects in light- and ischemia-induced retinal degeneration of animal
models [17]. It is thought that stem cells exhibit neuroprotection by
secreting neurotrophic factors, which promote tissue regeneration,
inhibit fibrosis and apoptosis, and modulate the immune system to
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reduce inflammation [24]. In particular, endothelial progenitor cells
(EPCs) and endothelial colony forming cells (ECFCs), a subtype
of EPCs, have displayed promising capabilities of incorporating
themselves into host retinal tissue and preventing dysfunctional
angiogenesis [17,25,26]. Clinical trials have reported adequate safety
and tolerance when evaluating stem cell treatment for photoreceptor
degenerative diseases. However, future studies are needed to enhance
knowledge of this type of therapy and to reinforce its efficacy [24,26].
Stargardt’s disease (STGD)
Stargardt’s disease (STGD) is caused by a number of mutations
to the ABCA4 gene [27]. Improper functioning of this transporter
protein results in all-trans-retinaldehyde buildup, collapsing the
visual cycle and leading to photoreceptor cell death. There is currently
no effective therapy for the disease, but there is hope for a solution
soon, as major progress has been in possible therapies. Direct gene
replacement, AAV gene delivery, and lentiviral gene delivery have all
been researched extensively, but lentiviral has been demonstrated to
be most effective due to its capacity to securely carry ABCA4 cDNA,
which is nearly 7kb [28]. There are also non-viral gene therapies,
mainly through nanoparticles, being researched.
Phase I/IIa clinical trials are being completed with lentiviral
vectors and compacted DNA nanoparticules to treat patients
[29]. A very recent publication using (1-aminoethyl)iminobis[N(oleoylcysteinyl-1-amino-ethyl)propio-namide (ECO) to transduce
wild-type ABCA4 into mice shows great promise [30]. ECO is
a pH-sensitive amino lipid that forms stable nanoparticles with
nucleic acids; with pABCA4 plasmids, ECO easily forms stable
nanoparticles. The ECO/pABCA4 nanoparticles self-assemble and
have in vitro transfection efficiency. This system needs to be further
modified to increase efficiency and enhance gene expression, but if
successful, a therapy with little to no side-effects due to the nature
of the nanoparticles could be used to treat STGD [30]. As ABCA4
malfunction applies to STGD, types of RP, cone-rod dystrophy, and
age-related macular degeneration, gene therapies to deliver functional
ABCA4 may also be useful in treating several other retinal diseases.

Conclusion
The publication of Visual cycle proteins: Structure, function, and
roles in human retinal disease highlighted the need to further explore
pathways in the visual cycle and related clinical investigations
including gene therapy. Recent discoveries about the role of IRBP,
DES1, and RGR have further clarified the understanding of visual
cycle pathway. Clinical trials are presently ongoing to test the
effectiveness of gene therapy treatments. As additional research is
conducted, our understanding of blinding diseases will be continual
to expand leading to the likelihood of future breakthroughs to novel
treatment of many ocular ailments.
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